Open-market purchases of Relmada Therapeutics, Inc. (RLMD) stock by its own executives, directors and 10% owners — every Form 4 buy of $250K or more that SPX Lens's daily insider scan has recorded, newest first.
| Scan | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Maged ShenoudaCFO | $844K | Added | |||
| Avg ~$4.22 (range $4.16-$4.25); tx dates 9/9-9/10/2026. Cluster: CEO Traversa also bought $828K same days. Now $4.52 (+7.1% since CFO buy). | ||||||
| Sep 14, 2026 | Sergio TraversaCEO | $828K | Added | |||
| Avg ~$4.14 (range $4.03-$4.18); tx dates 9/9-9/10/2026. Cluster: CFO Shenouda also bought $844K same days. Now $4.52 (+9.2% since CEO buy). | ||||||
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.